<p>this meta-analysis was conducted to investigate the clinical efficiency and safety of IC versus intravenous (IV) tirofiban in ACS patients undergoing PCI.</p
Background: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However...
Background Intracoronary (IC) administration of glycoprotein IIb/IIIa inhibitors (GPIs) has been stu...
Background: To determine whether intracoronary pro-urokinase or tirofiban improves myocardial reperf...
<p>this meta-analysis was conducted to investigate the clinical efficiency and safety of IC versus i...
<div><p>Background</p><p>Percutaneous coronary intervention (PCI) is known as the most effective tre...
WOS: 000281309900009PubMed ID: 20693130Objective: The purpose of this study was to compare the intra...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
The efficacy and safety of glycoprotein IIb/IIIa inhibitors via intracoronary (IC) route versus the ...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
heart disease Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary...
Background: Primary percutaneous coronary intervention (PCI) in patients with acute myocardial infar...
İstanbul Bilim Üniversitesi, Tıp Fakültesi.OBJECTIVE: The purpose of this study was to compare the i...
Background: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However...
Background Intracoronary (IC) administration of glycoprotein IIb/IIIa inhibitors (GPIs) has been stu...
Background: To determine whether intracoronary pro-urokinase or tirofiban improves myocardial reperf...
<p>this meta-analysis was conducted to investigate the clinical efficiency and safety of IC versus i...
<div><p>Background</p><p>Percutaneous coronary intervention (PCI) is known as the most effective tre...
WOS: 000281309900009PubMed ID: 20693130Objective: The purpose of this study was to compare the intra...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
The efficacy and safety of glycoprotein IIb/IIIa inhibitors via intracoronary (IC) route versus the ...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
heart disease Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary...
Background: Primary percutaneous coronary intervention (PCI) in patients with acute myocardial infar...
İstanbul Bilim Üniversitesi, Tıp Fakültesi.OBJECTIVE: The purpose of this study was to compare the i...
Background: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However...
Background Intracoronary (IC) administration of glycoprotein IIb/IIIa inhibitors (GPIs) has been stu...
Background: To determine whether intracoronary pro-urokinase or tirofiban improves myocardial reperf...
DOI
Add to ORKG